Dolby Laboratories [DLB] vs Cintas [CTAS] Detailed Stock Comparison
Dolby Laboratories
NYSE
Loading...
Cintas
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Dolby Laboratories wins in 10 metrics, Cintas wins in 9 metrics, with 0 ties. Dolby Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Dolby Laboratories | Cintas | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 25.86 | 50.23 | Dolby Laboratories |
| Price-to-Book Ratio | 2.58 | 19.05 | Dolby Laboratories |
| Debt-to-Equity Ratio | 1.50 | 56.67 | Dolby Laboratories |
| PEG Ratio | 18.40 | 47.33 | Dolby Laboratories |
| EV/EBITDA | 16.12 | 33.73 | Dolby Laboratories |
| Profit Margin (TTM) | 19.62% | 17.53% | Dolby Laboratories |
| Operating Margin (TTM) | 14.92% | 22.40% | Cintas |
| EBITDA Margin (TTM) | 14.92% | 22.40% | Cintas |
| Return on Equity | 10.50% | 40.27% | Cintas |
| Return on Assets (TTM) | 5.86% | 15.53% | Cintas |
| Free Cash Flow (TTM) | $297.25M | $1.76B | Cintas |
| Dividend Yield | N/A | 0.90% | N/A |
| 1-Year Return | -8.07% | 17.08% | Cintas |
| Price-to-Sales Ratio (TTM) | 4.99 | 8.63 | Dolby Laboratories |
| Enterprise Value | $6.07B | $91.65B | Cintas |
| EV/Revenue Ratio | 4.50 | 8.86 | Dolby Laboratories |
| Gross Profit Margin (TTM) | 86.06% | 49.71% | Dolby Laboratories |
| Revenue per Share (TTM) | $14 | $26 | Cintas |
| Earnings per Share (Diluted) | $2.71 | $4.41 | Cintas |
| Beta (Stock Volatility) | 0.91 | 1.04 | Dolby Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Dolby Laboratories vs Cintas Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Dolby Laboratories | -6.97% | -8.21% | -7.25% | -7.99% | -16.70% | -9.90% |
| Cintas | -0.47% | -0.92% | -1.25% | 5.70% | 9.54% | 21.64% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Dolby Laboratories | -8.07% | -10.63% | -0.11% | 105.42% | 11.50% | 270.65% |
| Cintas | 17.08% | 109.16% | 185.81% | 913.27% | 3,201.04% | 1,935.85% |
Performance & Financial Health Analysis: Dolby Laboratories vs Cintas
| Metric | DLB | CTAS |
|---|---|---|
| Market Information | ||
| Market Cap | $6.72B | $89.26B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 358,840 | 1,311,180 |
| 90 Day Avg. Volume | 373,870 | 1,481,540 |
| Last Close | $70.09 | $221.50 |
| 52 Week Range | $66.35 - $89.66 | $180.78 - $229.24 |
| % from 52W High | -21.83% | -3.38% |
| All-Time High | $104.74 (May 03, 2021) | $229.24 (Jun 06, 2025) |
| % from All-Time High | -33.08% | -3.38% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.08% |
| Quarterly Earnings Growth | 0.20% | 0.08% |
| Financial Health | ||
| Profit Margin (TTM) | 0.20% | 0.18% |
| Operating Margin (TTM) | 0.15% | 0.22% |
| Return on Equity (TTM) | 0.11% | 0.40% |
| Debt to Equity (MRQ) | 1.50 | 56.67 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $27.19 | $11.63 |
| Cash per Share (MRQ) | $7.30 | $0.66 |
| Operating Cash Flow (TTM) | $465.54M | $2.17B |
| Levered Free Cash Flow (TTM) | $375.60M | $1.56B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.90% |
| Last 12-Month Dividend | N/A | $2.01 |
Valuation & Enterprise Metrics Analysis: Dolby Laboratories vs Cintas
| Metric | DLB | CTAS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 25.86 | 50.23 |
| Forward P/E | 18.40 | 47.33 |
| PEG Ratio | 18.40 | 47.33 |
| Price to Sales (TTM) | 4.99 | 8.63 |
| Price to Book (MRQ) | 2.58 | 19.05 |
| Market Capitalization | ||
| Market Capitalization | $6.72B | $89.26B |
| Enterprise Value | $6.07B | $91.65B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.50 | 8.86 |
| Enterprise to EBITDA | 16.12 | 33.73 |
| Risk & Other Metrics | ||
| Beta | 0.91 | 1.04 |
| Book Value per Share (MRQ) | $27.19 | $11.63 |
Financial Statements Comparison: Dolby Laboratories vs Cintas
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DLB | CTAS |
|---|---|---|
| Revenue/Sales | $369.56M | $2.67B |
| Cost of Goods Sold | $35.84M | $1.34B |
| Gross Profit | $333.72M | $1.33B |
| Research & Development | $61.71M | N/A |
| Operating Income (EBIT) | $111.97M | $597.45M |
| EBITDA | $140.61M | $721.36M |
| Pre-Tax Income | $120.25M | $575.42M |
| Income Tax | $28.02M | $127.16M |
| Net Income (Profit) | $92.23M | $448.26M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DLB | CTAS |
|---|---|---|
| Cash & Equivalents | $626.55M | $263.97M |
| Total Current Assets | $1.39B | $3.44B |
| Total Current Liabilities | $457.49M | $1.64B |
| Long-Term Debt | $29.66M | $2.60B |
| Total Shareholders Equity | $2.58B | $4.68B |
| Retained Earnings | $2.60B | $11.80B |
| Property, Plant & Equipment | $264.92M | $3.50B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DLB | CTAS |
|---|---|---|
| Operating Cash Flow | $129.41M | $599.12M |
| Capital Expenditures | $-6.90M | $0 |
| Free Cash Flow | $168.00M | $521.13M |
| Debt Repayment | N/A | $-450.00M |
| Common Stock Repurchase | $-36.51M | $-256.67M |
Short Interest & Institutional Ownership Analysis
| Metric | DLB | CTAS |
|---|---|---|
| Shares Short | 1.45M | 5.45M |
| Short Ratio | 3.72 | 3.93 |
| Short % of Float | 0.04% | 0.02% |
| Average Daily Volume (10 Day) | 358,840 | 1,311,180 |
| Average Daily Volume (90 Day) | 373,870 | 1,481,540 |
| Shares Outstanding | 95.39M | 402.95M |
| Float Shares | 60.46M | 342.35M |
| % Held by Insiders | 0.01% | 0.15% |
| % Held by Institutions | 0.96% | 0.68% |
Dividend Analysis & Yield Comparison: Dolby Laboratories vs Cintas
| Metric | DLB | CTAS |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.01 |
| Last 12-Month Dividend Yield | N/A | 0.90% |
| 3-Year Avg Annual Dividend | N/A | $1.51 |
| 3-Year Avg Dividend Yield | N/A | 0.22% |
| 3-Year Total Dividends | N/A | $4.53 |
| Ex-Dividend Date | N/A | Aug 15, 2025 |